Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Cutaneous Dermatomyositis
NCT05361109Phase 2Withdrawn
- Sponsor
- University of Washington
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baricitinib in dermatomyositis (DM), sponsored by University of Washington. Primary endpoint: Cutaneous Disease Activity Severity Index at 24 weeks. Planned start Jun 2022; status: withdrawn.
02
Drugs
baricitinib
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05361109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361109.